{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:59:19Z","timestamp":1794488359622,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005632","name":"Ministry of Science and Higher Education | Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["FENG.01.01-IP.01-1001\/23"],"award-info":[{"award-number":["FENG.01.01-IP.01-1001\/23"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Ministry of Science and Higher Education | Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["POIR.01.01.01-00-0740\/19"],"award-info":[{"award-number":["POIR.01.01.01-00-0740\/19"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Chem"],"DOI":"10.1038\/s42004-025-01641-9","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T11:42:44Z","timestamp":1755171764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-1085","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Glaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Pluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztofa E.","family":"Odrzyw\u00f3\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Klejnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Cottens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Coppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Dobrza\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Drmota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Lis-Grze\u015bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"\u015anie\u017cewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Majkut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Mianowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8791-8331","authenticated-orcid":false,"given":"Paulina","family":"Rozborska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jarmuszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kaczanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Adamska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sawicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4553-0908","authenticated-orcid":false,"given":"Anna","family":"Serwotka-Suszczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Makowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Gajewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Leszkowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Mankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Przytulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Wi\u015bniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Szlachcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142 J.","family":"Walczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"1641_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global, regional and national burden of primary liver cancer by subtype. Eur. J. Cancer 161, 108\u2013118 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1641_CR2","unstructured":"IARC (2024) https:\/\/gco.iarc.fr\/en."},{"key":"1641_CR3","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer, M. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 4, e609\u2013e616 (2016).","journal-title":"Lancet Glob. Health"},{"key":"1641_CR4","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju, T. et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol. 3, 1683 (2017).","journal-title":"JAMA Oncol."},{"key":"1641_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn, K. A., Petrick, J. L. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma. Hepatology 73, 4\u201313 (2021).","journal-title":"Hepatology"},{"key":"1641_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/cncr.29971","volume":"122","author":"OV Makarova-Rusher","year":"2016","unstructured":"Makarova-Rusher, O. V. et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 122, 1757\u20131765 (2016).","journal-title":"Cancer"},{"key":"1641_CR7","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/ajg.2013.160","volume":"108","author":"TM Welzel","year":"2013","unstructured":"Welzel, T. M. et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the united states. Am. J. Gastroenterol. 108, 1314\u20131321 (2013).","journal-title":"Am. J. Gastroenterol."},{"key":"1641_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/jnci\/djr395","volume":"103","author":"D Trichopoulos","year":"2011","unstructured":"Trichopoulos, D. et al. Hepatocellular carcinoma risk factors and disease burden in a european cohort: a nested case-control study. JNCI J. Natl Cancer Inst. 103, 1686\u20131695 (2011).","journal-title":"JNCI J. Natl Cancer Inst."},{"key":"1641_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681\u2013693 (2022).","journal-title":"J. Hepatol."},{"key":"1641_CR10","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan, J. D. et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J. Clin. Oncol. 42, 1830\u20131850 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1641_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","volume":"162","author":"GL Su","year":"2022","unstructured":"Su, G. L. et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology 162, 920\u2013934 (2022).","journal-title":"Gastroenterology"},{"key":"1641_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11596-022-2665-6","volume":"43","author":"Y Xi","year":"2023","unstructured":"Xi, Y. et al. GSPT1 Functions as a tumor promoter in human liver cancer. Curr. Med. Sci. 43, 104\u2013114 (2023).","journal-title":"Curr. Med. Sci."},{"key":"1641_CR13","doi-asserted-by":"publisher","first-page":"10354","DOI":"10.18632\/aging.202796","volume":"13","author":"X Long","year":"2021","unstructured":"Long, X., Zhao, L., Li, G., Wang, Z. & Deng, Z. Identification of GSPT1 as prognostic biomarker and promoter of malignant colon cancer cell phenotypes via the GSK-3\u03b2\/CyclinD1 pathway. Aging 13, 10354\u201310368 (2021).","journal-title":"Aging"},{"key":"1641_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06967-1","volume":"15","author":"T Sasayama","year":"2024","unstructured":"Sasayama, T. et al. Potential of GSPT1 as a novel target for glioblastoma therapy. Cell Death Dis. 15, 572 (2024).","journal-title":"Cell Death Dis."},{"key":"1641_CR15","doi-asserted-by":"publisher","first-page":"18620","DOI":"10.18632\/oncotarget.7620","volume":"7","author":"L Zhou","year":"2016","unstructured":"Zhou, L. et al. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo. Oncotarget 7, 18620\u201318630 (2016).","journal-title":"Oncotarget"},{"key":"1641_CR16","first-page":"1171","volume":"369","author":"KJ Yong","year":"2013","unstructured":"Yong, K. J., Chai, L. & Tenen, D. G. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N. Engl. J. Med. 369, 1171\u20131172 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1641_CR17","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3748\/wjg.v22.i9.2837","volume":"22","author":"F Yin","year":"2016","unstructured":"Yin, F., Han, X., Yao, S.-K., Wang, X.-L. & Yang, H.-C. Importance of SALL4 in the development and prognosis of hepatocellular carcinoma. World J. Gastroenterol. 22, 2837\u20132843 (2016).","journal-title":"World J. Gastroenterol."},{"key":"1641_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","volume":"61","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J. Med Chem. 61, 535\u2013542 (2018).","journal-title":"J. Med Chem."},{"key":"1641_CR19","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund, C. C. et al. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 5, e354\u2013e354 (2015).","journal-title":"Blood Cancer J."},{"key":"1641_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 164, 811\u2013821 (2014).","journal-title":"Br. J. Haematol."},{"key":"1641_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s42003-020-01240-5","volume":"3","author":"S Yamanaka","year":"2020","unstructured":"Yamanaka, S. et al. An IMiD-induced SALL4 degron system for selective degradation of target proteins. Commun. Biol. 3, 515 (2020).","journal-title":"Commun. Biol."},{"key":"1641_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40385-9","volume":"14","author":"S Yamanaka","year":"2023","unstructured":"Yamanaka, S. et al. Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation. Nat. Commun. 14, 4683 (2023).","journal-title":"Nat. Commun."},{"key":"1641_CR23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124297","author":"C-X Shi","year":"2015","unstructured":"Shi, C.-X. et al. Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma. Haematologica https:\/\/doi.org\/10.3324\/haematol.2015.124297 (2015).","journal-title":"Haematologica"},{"key":"1641_CR24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/cancers16071319","volume":"16","author":"B Chowdhury","year":"2024","unstructured":"Chowdhury, B. et al. Synergy between BRD9- and IKZF3-targeting as a therapeutic strategy for multiple myeloma. Cancers (Basel) 16, 1319 (2024).","journal-title":"Cancers (Basel)"},{"key":"1641_CR25","doi-asserted-by":"crossref","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 7 (2018).","DOI":"10.7554\/eLife.38430"},{"key":"1641_CR26","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981\u2013987 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1641_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","volume":"64","author":"JD Hansen","year":"2021","unstructured":"Hansen, J. D. et al. CC-90009: a cereblon E3 Ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia. J. Med. Chem. 64, 1835\u20131843 (2021).","journal-title":"J. Med. Chem."},{"key":"1641_CR28","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1111\/bph.13573","volume":"173","author":"AG Jarnicki","year":"2016","unstructured":"Jarnicki, A. G. et al. The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model. Br. J. Pharm. 173, 3161\u20133175 (2016).","journal-title":"Br. J. Pharm."},{"key":"1641_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1006\/abio.1997.2391","volume":"253","author":"M Zhou","year":"1997","unstructured":"Zhou, M., Diwu, Z., Panchuk-Voloshina, N. & Haugland, R. P. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal. Biochem 253, 162\u2013168 (1997).","journal-title":"Anal. Biochem"},{"key":"1641_CR30","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1007\/s00011-009-0135-2","volume":"59","author":"HG Schwelberger","year":"2010","unstructured":"Schwelberger, H. G. Structural organization of mammalian copper-containing amine oxidase genes. Inflamm. Res. 59, S223\u2013S225 (2010).","journal-title":"Inflamm. Res."},{"key":"1641_CR31","doi-asserted-by":"publisher","first-page":"106571","DOI":"10.1016\/j.ympev.2019.106571","volume":"139","author":"L Lopes de Carvalho","year":"2019","unstructured":"Lopes de Carvalho, L., Bligt-Lind\u00e9n, E., Ramaiah, A., Johnson, M. S. & Salminen, T. A. Evolution and functional classification of mammalian copper amine oxidases. Mol. Phylogenet Evol. 139, 106571 (2019).","journal-title":"Mol. Phylogenet Evol."},{"key":"1641_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"1641_CR33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","volume":"3","author":"A Mares","year":"2020","unstructured":"Mares, A. et al. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2. Commun. Biol. 3, 140 (2020).","journal-title":"Commun. Biol."},{"key":"1641_CR34","doi-asserted-by":"publisher","first-page":"23327","DOI":"10.1002\/anie.202109237","volume":"60","author":"RP Law","year":"2021","unstructured":"Law, R. P. et al. Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs. Angew. Chem. Int. Ed. 60, 23327\u201323334 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1641_CR35","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","volume":"28","author":"E Izumchenko","year":"2017","unstructured":"Izumchenko, E. et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol. 28, 2595\u20132605 (2017).","journal-title":"Ann. Oncol."},{"key":"1641_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jhep.2019.08.017","volume":"72","author":"S Rebouissou","year":"2020","unstructured":"Rebouissou, S. & Nault, J.-C. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J. Hepatol. 72, 215\u2013229 (2020).","journal-title":"J. Hepatol."},{"key":"1641_CR37","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood.2020008676","volume":"137","author":"C Surka","year":"2021","unstructured":"Surka, C. et al. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood 137, 661\u2013677 (2021).","journal-title":"Blood"},{"key":"1641_CR38","doi-asserted-by":"crossref","unstructured":"Sellar, R. S. et al. Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells. J. Clin. Investig. 132 (2022).","DOI":"10.1172\/JCI153514"},{"key":"1641_CR39","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1021\/acs.jmedchem.0c01313","volume":"64","author":"G Nishiguchi","year":"2021","unstructured":"Nishiguchi, G. et al. Identification of potent, selective, and orally bioavailable small-molecule GSPT1\/2 degraders from a focused library of cereblon modulators. J. Med. Chem. 64, 7296\u20137311 (2021).","journal-title":"J. Med. Chem."},{"key":"1641_CR40","unstructured":"Zeidan, A. M. et al. e-Poster # EP598: Clinical activity of CC-90009, a cereblon E3 ligase modulator and first-in-class GSPT1 degrader, as a single agent in patients with relapsed or refractory acute myeloid leukemia: First results from a phase 1 dose-finding study (EHA Library, 2020). https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/294516\/amer.m.zeidan.results.from.a.phase.1.dose-finding.study.of.cc-90009.a.cereblon.html."},{"key":"1641_CR41","unstructured":"MonteRosa Therapeutics, A. G. MonteRosa Corporate Presentation\u20142025: Proteome Editing Through Molecular Glue Degraders (2025). https:\/\/Ir.Monterosatx.Com\/Static-Files\/3d92beb3-2d3b-45c9-91cf-C7d2e0545b96 (Accessed 11 February 2025)."},{"key":"1641_CR42","doi-asserted-by":"publisher","unstructured":"Petzold, G. et al. Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition (2024). https:\/\/doi.org\/10.1101\/2024.10.07.616933.","DOI":"10.1101\/2024.10.07.616933"},{"key":"1641_CR43","doi-asserted-by":"publisher","unstructured":"Sylvain, A. et al. A cereblon (CRBN) molecular glue degrader of NIMA-related kinase 7 (NEK7) reveals a context-dependent role in NLRP3 inflammasome activation (2024). https:\/\/doi.org\/10.1101\/2024.11.06.622079.","DOI":"10.1101\/2024.11.06.622079"},{"key":"1641_CR44","doi-asserted-by":"crossref","unstructured":"Chen, L. et al. Selective and potent molecular glue degraders for NIMA-related kinase 7. Angew. Chemie Int. Edn. 64 (2025).","DOI":"10.1002\/anie.202500169"},{"key":"1641_CR45","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","volume":"80","author":"S Das","year":"2020","unstructured":"Das, S., Shapiro, B., Vucic, E. A., Vogt, S. & Bar-Sagi, D. Tumor cell-derived IL1\u03b2 promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 80, 1088\u20131101 (2020).","journal-title":"Cancer Res."},{"key":"1641_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48794-x","volume":"9","author":"HE Lee","year":"2019","unstructured":"Lee, H. E. et al. Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells. Sci. Rep. 9, 12277 (2019).","journal-title":"Sci. Rep."},{"key":"1641_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00341-5","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang, J. & Veeramachaneni, N. Targeting interleukin-1\u03b2 and inflammation in lung cancer. Biomark. Res. 10, 5 (2022).","journal-title":"Biomark. Res."},{"key":"1641_CR48","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","volume":"570","author":"H Sharif","year":"2019","unstructured":"Sharif, H. et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature 570, 338\u2013343 (2019).","journal-title":"Nature"},{"key":"1641_CR49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1124\/dmd.118.085811","volume":"47","author":"MJ Reid","year":"2019","unstructured":"Reid, M. J., Eyre, R. & Podoll, T. Oxidative deamination of emixustat by human vascular adhesion protein-1\/semicarbazide-sensitive amine oxidase. Drug Metab. Disposition 47, 504\u2013515 (2019).","journal-title":"Drug Metab. Disposition"},{"key":"1641_CR50","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1172\/JCI73722","volume":"125","author":"CJ Weston","year":"2015","unstructured":"Weston, C. J. et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J. Clin. Investig. 125, 501\u2013520 (2015).","journal-title":"J. Clin. Investig."},{"key":"1641_CR51","doi-asserted-by":"crossref","unstructured":"Chen, S.-C. et al. Serum vascular adhesion protein-1 is associated with twelve-year risk of incident cancer, cancer mortality, and all-cause mortality: a community-based cohort study. Front. Oncol 13 (2023).","DOI":"10.3389\/fonc.2023.1308353"},{"key":"1641_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2183-7","volume":"16","author":"ST Ward","year":"2016","unstructured":"Ward, S. T. et al. Evaluation of serum and tissue levels of VAP-1 in colorectal cancer. BMC Cancer 16, 154 (2016).","journal-title":"BMC Cancer"},{"key":"1641_CR53","first-page":"1","volume":"2016","author":"Z Hu","year":"2016","unstructured":"Hu, Z. et al. Evaluation of serum vascular adhesion protein-1 as a potential biomarker in thyroid cancer. Int. J. Endocrinol. 2016, 1\u20137 (2016).","journal-title":"Int. J. Endocrinol."},{"key":"1641_CR54","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1084\/jem.178.6.2255","volume":"178","author":"M Salmi","year":"1993","unstructured":"Salmi, M., Kalimo, K. & Jalkanen, S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J. Exp. Med 178, 2255\u20132260 (1993).","journal-title":"J. Exp. Med"},{"key":"1641_CR55","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/ars.2017.7418","volume":"30","author":"M Salmi","year":"2019","unstructured":"Salmi, M. & Jalkanen, S. Vascular adhesion protein-1: a cell surface amine oxidase in translation. Antioxid. Redox Signal 30, 314\u2013332 (2019).","journal-title":"Antioxid. Redox Signal"},{"key":"1641_CR56","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s10753-017-0628-z","volume":"40","author":"C Cai","year":"2017","unstructured":"Cai, C. et al. NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid. Inflammation 40, 1875\u20131883 (2017).","journal-title":"Inflammation"},{"key":"1641_CR57","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/jgh.16674","volume":"39","author":"C Chu","year":"2024","unstructured":"Chu, C. et al. Interleukin-1 receptor 1 deficiency worsens hepatocellular carcinoma, while gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in intra-hepatic immune cells. J. Gastroenterol. Hepatol. 39, 2208\u20132218 (2024).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1641_CR58","doi-asserted-by":"publisher","first-page":"e1003330","DOI":"10.1371\/journal.ppat.1003330","volume":"9","author":"AA Negash","year":"2013","unstructured":"Negash, A. A. et al. IL-1\u03b2 Production through the NLRP3 inflammasome by hepatic macrophages links Hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 9, e1003330 (2013).","journal-title":"PLoS Pathog."},{"key":"1641_CR59","doi-asserted-by":"publisher","unstructured":"Meents, A. et al. Development of an in-vacuum x-ray microscope with cryogenic sample cooling for beamline P11 at PETRA III. in (ed. Lai, B.) 88510K (2013). https:\/\/doi.org\/10.1117\/12.2027303.","DOI":"10.1117\/12.2027303"},{"key":"1641_CR60","volume":"131","author":"A Burkhardt","year":"2016","unstructured":"Burkhardt, A. et al. Status of the crystallography beamlines at PETRA III. Eur. Phys. J. 131, 56 (2016).","journal-title":"Eur. Phys. J."},{"key":"1641_CR61","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"WXDS Kabsch","year":"2010","unstructured":"Kabsch, W. X. D. S. Acta Crystallogr. D: Biol. Crystallogr. 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"1641_CR62","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl Crystallogr."},{"key":"1641_CR63","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D: Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"1641_CR64","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1107\/S0907444911001314","volume":"67","author":"GN Murshudov","year":"2011","unstructured":"Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D: Biol. Crystallogr. 67, 355\u2013367 (2011).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"1641_CR65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1107\/S2059798317000067","volume":"73","author":"F Long","year":"2017","unstructured":"Long, F. et al. AceDRG: a stereochemical description generator for ligands. Acta Crystallogr D: Struct. Biol. 73, 112\u2013122 (2017).","journal-title":"Acta Crystallogr D: Struct. Biol."}],"container-title":["Communications Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01641-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01641-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01641-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:30:49Z","timestamp":1757457049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01641-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1641"],"URL":"https:\/\/doi.org\/10.1038\/s42004-025-01641-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.06.25.661504","asserted-by":"object"}]},"ISSN":["2399-3669"],"issn-type":[{"value":"2399-3669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are or were employees and stockholders of Captor Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}